707 related articles for article (PubMed ID: 17046212)
1. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
3. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
4. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
5. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
DeRyke CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
Crandon JL; Kuti JL; Jones RN; Nicolau DP
Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
[TBL] [Abstract][Full Text] [Related]
9. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Santos Filho L; Eagye KJ; Kuti JL; Nicolau DP
Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
[TBL] [Abstract][Full Text] [Related]
10. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Maglio D; Kuti JL; Nicolau DP
Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
[TBL] [Abstract][Full Text] [Related]
11. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
14. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
Masterton RG; Kuti JL; Turner PJ; Nicolau DP
J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
16. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
19. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.
Courter JD; Kuti JL; Girotto JE; Nicolau DP
Pediatr Blood Cancer; 2009 Sep; 53(3):379-85. PubMed ID: 19422028
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
Lomaestro BM; Drusano GL
Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]